Medicenna Therapeutics

MDNAF Lead: Phase 2 ★ Read the deep dive → 9 Biotech Distilled articles ↓

Most recent annual filing: 2023-06-27

Catalyst timeline

MDNA11 interim2H 2026MDNA11 interim, 2H 2026, material
MDNA11 FDA feedback2H 2026MDNA11 FDA feedback, 2H 2026, notable
MDNA11 SITC Ph1 toplineNov 7, 2026MDNA11 SITC Ph1 topline, Nov 7, 2026, major
MDNA113 IND filing2027MDNA113 IND filing, 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

bizaxofusp

MDNA55

Protein Target: IL-4R, IL-4

Recurrent Glioblastoma Phase 2 intratumoral NCT02858895

MDNA11

Protein Target: IL-2Rβ, CD122, IL-2

Solid Tumors Phase 1 Phase 1/2 trial intravenous Merck NCT05086692
Melanoma Phase 1 Fondazione Melanoma Onlus NCT05086692

MDNA19

Protein Target: IL-2Rβ, CD122

Undisclosed indication Preclinical

MDNA223

Protein Target: PD-1, IL-2Rβ

Undisclosed indication Preclinical

MDNA413

Protein Target: IL-4R, IL-13Rα1

Undisclosed indication Preclinical

MDNA132

Protein Target: IL-13Rα2

Undisclosed indication Preclinical

MDNA213

Protein Target: IL-13Rα2

Undisclosed indication Preclinical

MDNA209

Protein Target: IL-2Rβ

Undisclosed indication Preclinical

MDNA113

Protein Target: PD-1, IL-2, IL-13Rα2

Undisclosed indication Preclinical

Technology platforms

BiSKITs

Bi-functional SuperKine ImmunoTherapies platform that fuses IL-2, IL-4, and/or IL-13 Superkines with proteins, antibodies, checkpoint inhibitors, or other Superkines to create dual-function molecules for treatment of cancers, including immunologically cold tumors

Targets: IL-2Rβ, PD-1, IL-4R, IL-13Rα2, IL-2

T-MASK

Targeted Metalloprotease Activated SuperKine platform — conditionally activates IL-2 Superkine payloads via tumor-associated MMP cleavage and proximity-dependent unmasking in the tumor microenvironment; focus on solid tumors

Targets: MMP, IL-13Rα2, PD-1, IL-2, CD122, IL-15

BiSKIT

Proprietary bifunctional immunotherapy platform used to develop PD-1 x IL-2 bifunctional candidates for solid tumors

Targets: PD-1, IL-2

Biotech Distilled coverage (9)

2026-10-02 UPDATE: Medicenna Therapeutics (MDNAF) - The Reverse Split Gets a Green Light
2026-08-15 UPDATE: Medicenna Therapeutics (MDNAF) - Two Oral Slots, One Slipped IND, and Sorbie Still in Forward-Looking Tense 🔒 Paid
2026-06-26 UPDATE: Medicenna Therapeutics (MDNAF) - FY2026 Results, a “Fractional” CMO, and the Sorbie Clock 🔒 Paid
2026-05-28 UPDATE: Medicenna Therapeutics (MDNAF) - The Marketed Tranche Closes at CDN$4.44M, Sorbie Still Pending 🔒 Paid
2026-05-22 UPDATE: Medicenna Therapeutics (MDNAF) - The Prospectus Supplement Drops, and a Sorbie Wrinkle Appears 🔒 Paid
2026-05-19 UPDATE: Medicenna Therapeutics (MDNAF) - The Pricing Print Lands, and the Tape Tells You Everything 🔒 Paid
2026-05-14 UPDATE: Medicenna Therapeutics (MDNAF) - The Dilution Headline Lands 🔒 Paid
2026-04-27 UPDATE: Medicenna Therapeutics (MDNAF) - The Science Wins, the Cash Cliff Looms Closer 🔒 Paid
2026-03-20 Medicenna Therapeutics (MDNAF) - Scientific Deep Dive for MDNA11 and Pipeline Products

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.